All Stories

  1. The Pharmacological Evidences for the Involvement of AhR and GPR35 Receptors in Kynurenic Acid-Mediated Cytokine and Chemokine Secretion by THP-1-Derived Macrophages
  2. Cell-Specific Vulnerability of Human Glioblastoma and Astrocytoma Cells to Mephedrone—An In Vitro Study
  3. The Effects of Kynurenic Acid in Zebrafish Embryos and Adult Rainbow Trout
  4. Determination of Bioactive Compound Kynurenic Acid in Linum usitatissimum L.
  5. Developmental Exposure to Kynurenine Affects Zebrafish and Rat Behavior
  6. Fetal sex as moderating factor for the relationship between maternal childhood trauma and salivary kynurenic acid and tryptophan in pregnancy: A pilot study
  7. LC–MS/MS-based quantification of tryptophan, kynurenine, and kynurenic acid in human placental, fetal membranes, and umbilical cord samples
  8. A Review of the Health Benefits of Food Enriched with Kynurenic Acid
  9. Evidence against involvement of kynurenate branch of kynurenine pathway in pathophysiology of Fuchs’ dystrophy and keratoconus
  10. The Effect of Thermal Treatment on Selected Properties and Content of Biologically Active Compounds in Potato Crisps
  11. Content of tryptophan and kynurenines in serum and milk of dairy cows with mastitis caused by Streptococcus spp.
  12. Kynurenic Acid Accelerates Healing of Corneal Epithelium In Vitro and In Vivo
  13. Effect of 4-week physical exercises on tryptophan, kynurenine and kynurenic acid content in human sweat
  14. Tryptophan as a Safe Compound in Topical Ophthalmic Medications: In Vitro and In Vivo Studies
  15. Tryptophan Pathway Abnormalities in a Murine Model of Hereditary Glaucoma
  16. Improved Production of Kynurenic Acid by Yarrowia lipolytica in Media Containing Different Honeys
  17. LC-QTOF/MS determination of tryptophan and kynurenine in infant formulas
  18. HPLC Gradient Retention of Tryptophan and its Metabolites on Three Stationary Phases in Context of Lipophilicity Assessment
  19. AhR and IDO1 in pathogenesis of Covid-19 and the “Systemic AhR Activation Syndrome:” a translational review and therapeutic perspectives
  20. The Influence of Palmatine Isolated from Berberis sibirica Radix on Pentylenetetrazole-Induced Seizures in Zebrafish
  21. An efficient method for production of kynurenic acid by Yarrowia lipolytica
  22. Lipophilicity of tryptophan, its metabolites and derivatives measured by thin-layer chromatography
  23. Phenotypic Characterization of Larval Zebrafish (Danio rerio) with Partial Knockdown of the cacna1a Gene
  24. Kynurenic acid selectively reduces heart rate in spontaneously hypertensive rats
  25. Kynurenic acid and cancer: facts and controversies
  26. Tryptophan and Kynurenine Pathway Metabolites in Animal Models of Retinal and Optic Nerve Damage: Different Dynamics of Changes
  27. Changes in tryptophan and kynurenine pathway metabolites in the blood of children treated with ketogenic diet for refractory epilepsy
  28. Kynurenic acid as the neglected ingredient of commercial baby formulas
  29. Quinaldic acid induces changes in the expression of p53 tumor suppressor both on protein and gene level in colon cancer LS180 cells
  30. The presence and distribution of G protein-coupled receptor 35 (GPR35) in the human cornea – Evidences from in silico gene expression analysis and immunodetection
  31. Examination of Kynurenine Toxicity on Corneal and Conjunctival Epithelium: In vitro and in vivo Studies
  32. Fate and distribution of kynurenic acid administered as beverage
  33. Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro
  34. Kynurenic Acid Protects against Thioacetamide-Induced Liver Injury in Rats
  35. Influence of Cyclooxygenase-2 Inhibitors on Kynurenic Acid Production in Rat Brain in Vitro
  36. Tryptophan, kynurenine, kynurenic acid concentrations and indoleamine 2,3-dioxygenase activity in serum and milk of dairy cows with subclinical mastitis caused by coagulase-negative staphylococci
  37. Effect of Kynurenic Acid on Pupae Viability of Drosophila melanogaster cinnabar and cardinal Eye Color Mutants with Altered Tryptophan-Kynurenine Metabolism
  38. Quinaldic acid in synovial fluid of patients with rheumatoid arthritis and osteoarthritis and its effect on synoviocytes in vitro
  39. Kynurenic Acid and Neuroprotective Activity of the Ketogenic Diet in the Eye
  40. Effects of tryptophan, kynurenine and kynurenic acid exerted on human reconstructed corneal epithelium in vitro
  41. Angiotensin II Type 1 Receptor Blockers Inhibit KAT II Activity in the Brain—Its Possible Clinical Applications
  42. The effect of three angiotensin-converting enzyme inhibitors on kynurenic acid production in rat kidney in vitro
  43. Influence of picolinic acid on seizure susceptibility in mice
  44. Successful treatment of anti-NMDA receptor encephalitis with a prompt ovarian tumour removal and prolonged course of plasmapheresis: A case report
  45. Angiotensin-converting enzyme inhibitors modulate kynurenic acid production in rat brain cortex in vitro
  46. Kynurenic Acid Induces Impairment of Oligodendrocyte Viability: On the Role of Glutamatergic Mechanisms
  47. Protective action of nicotinic acid benzylamide in a variety of chemically-induced seizures in mice
  48. The effect of kynurenic acid on the synthesis of selected cytokines by murine splenocytes – in vitro and ex vivo studies
  49. Prolonged Subdural Infusion of Kynurenic Acid Is Associated with Dose-Dependent Myelin Damage in the Rat Spinal Cord
  50. Cholinesterase activity in blood and pesticide presence in sweat as biomarkers of children`s environmental exposure to crop protection chemicals
  51. Trace metal analyses in honey samples from selected countries. A potential use in bio-monitoring
  52. Quinaldic acid inhibits proliferation of colon cancer HT-29 cells in vitro: Effects on signaling pathways
  53. Serum tryptophan and its metabolites in female dogs undergoing ovariohysterectomy as treatment of pyometra or as elective spay surgery
  54. Kynurenic Acid Content in Selected Culinary Herbs and Spices
  55. On the toxicity of kynurenic acid in vivo and in vitro
  56. Effects of systemic administration of kynurenic acid and glycine on renal haemodynamics and excretion in normotensive and spontaneously hypertensive rats
  57. Kynurenic acid inhibits colon cancer proliferation in vitro: effects on signaling pathways
  58. Modulation by kynurenine of extracellular kynurenate and glutamate in cerebral cortex of rats with acute liver failure
  59. Orphenadrine-induced convulsive status epilepticus in rats responds to the NMDA antagonist dizocilpine
  60. Kynurenic acid inhibits proliferation and migration of human glioblastoma T98G cells
  61. Effect of oral administration of kynurenic acid on the activity of the peripheral blood leukocytes in mice
  62. The in vitro effect of kynurenic acid on the rainbow trout (Oncorhynchus mykiss) leukocyte and splenocyte activity
  63. Disturbances of Tryptophan Metabolism and Risk of Depression in HCV Patients Treated with IFN-Alpha
  64. Presence and distribution of l-kynurenine aminotransferases immunoreactivity in human cataractous lenses
  65. Effect of dietary administration of kynurenic acid on the activity of splenocytes of the rainbow trout (Oncorhynchus mykiss)
  66. Tryptophan-Kynurenine Metabolism and Insulin Resistance in Hepatitis C Patients
  67. Kynurenic acid – a new tool in the treatment of hiperhomocysteinemia and its consequences?
  68. Kynurenic acid enhances expression of p21 Waf1/Cip1 in colon cancer HT-29 cells
  69. Potato- An Important Source of Nutritional Kynurenic Acid
  70. Kynurenic acid in human renal cell carcinoma: its antiproliferative and antimigrative action on Caki-2 cells
  71. Main dietary compounds and pancreatic cancer risk. The quantitative analysis of case–control and cohort studies
  72. Ketogenic diet increases concentrations of kynurenic acid in discrete brain structures of young and adult rats
  73. Kynurenic acid and kynurenine aminotransferases in retinal aging and neurodegeneration
  74. Kynurenic acid synthesis and kynurenine aminotransferases expression in colon derived normal and cancer cells
  75. Nefopam enhances the protective activity of antiepileptics against maximal electroshockinduced convulsions in mice
  76. Orphenadrine induces secondarily generalized convulsive status epilepticus in rats
  77. Distribution, Synthesis, and Absorption of Kynurenic Acid in Plants
  78. Neuroprotection by acetoacetate and β-hydroxybutyrate against NMDA-induced RGC damage in rat—possible involvement of kynurenic acid
  79. Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats
  80. Kynurenic acid in blood and bone marrow plasma of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patients
  81. Long-term exposure to nicotine markedly reduces kynurenic acid in rat brain — In vitro and ex vivo evidence
  82. Influence of orphenadrine upon the protective activity of various antiepileptics in the maximal electroshock-induced convulsions in mice
  83. Kynurenic acid protects against the homo-cysteine-induced impairment of endothelial cells
  84. High concentration of kynurenic acid in bile and pancreatic juice
  85. Sedative and anticonvulsant drugs suppress postnatal neurogenesis
  86. Anticonvulsant and acute adverse effect profiles of picolinic acid 2-fluoro-benzylamide in various experimental seizure models and chimney test in mice
  87. Micromolar concentration of kynurenic acid in rat small intestine
  88. Presence of kynurenic acid in food and honeybee products
  89. Characterization of the anticonvulsant profile of isonicotinic acid benzylamide in various experimental seizure models in mice
  90. Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis
  91. NMDA antagonists exert distinct effects in experimental organophosphate or carbamate poisoning in mice
  92. Lithium–methomyl induced seizures in rats: A new model of status epilepticus?
  93. Elevated Concentrations of Kynurenic Acid, a Tryptophan Derivative, in Dense Nuclear Cataracts
  94. Ammonia at pathophysiologically relevant concentrations activates kynurenic acid synthesis in cultured astrocytes and neurons
  95. Enhancement of brain kynurenic acid production by anticonvulsants—Novel mechanism of antiepileptic activity?
  96. Effect of glutamate receptor antagonists and antirheumatic drugs on proliferation of synoviocytes in vitro
  97. Kynurenic acid synthesis in bovine retinal slices – effect of glutamate agonists
  98. Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid, inhibits proliferation of synoviocytes in vitro
  99. Demonstration of Kynurenine Aminotransferases I and II and Characterization of Kynurenic Acid Synthesis in Oligodendrocyte Cell Line (OLN-93)
  100. Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in cultured cerebral cortical neurons
  101. Dual effect ofDL-homocysteine andS-adenosylhomocysteine on brain synthesis of the glutamate receptor antagonist, kynurenic acid
  102. Ethosuximide and valproate display high efficacy against lindane-induced seizures in mice
  103. Carbamazepine enhances brain production of kynurenic acid in vitro
  104. Age-dependent decrease of retinal kynurenate and kynurenine aminotransferases in DBA/2J mice, a model of ocular hypertension
  105. Kynurenic acid in ALS patients
  106. Kynurenic acid production in cultured bovine aortic endothelial cells. Homocysteine is a potent inhibitor
  107. Kynurenic acid synthesis in cerebral cortical slices of rats with progressing symptoms of thioacetamide-induced hepatic encephalopathy
  108. Content of Kynurenic Acid and Activity of Kynurenine Aminotransferases in Mammalian Eyes
  109. Expression of kynurenine aminotransferases in the rat retina during development
  110. l-Cysteine sulphinate, endogenous sulphur-containing amino acid, inhibits rat brain kynurenic acid production via selective interference with kynurenine aminotransferase II
  111. Ontogenic changes of kynurenine aminotransferase I activity and its expression in the chicken retina
  112. Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis
  113. Dizocilpine Improves Beneficial Effects of Cholinergic Antagonists in Anticholinesterase-Treated Mice
  114. Alterations of kynurenic acid content in the retina in response to retinal ganglion cell damage
  115. Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients
  116. 1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats
  117. Changes of kynurenic acid content in the rat and chicken retina during ontogeny
  118. Regulation of kynurenic acid synthesis in C6 glioma cells
  119. Presence of kynurenic acid and kynurenine aminotransferases in the inner retina
  120. AMPA and GABAB receptor antagonists and their interaction in rats with a genetic form of absence epilepsy
  121. Protective effect of adenosine receptor agonists in a new model of epilepsy – seizures evoked by mitochondrial toxin, 3-nitropropionic acid, in mice
  122. Amlodipine enhances the activity of antiepileptic drugs against pentylenetetrazole-induced seizures
  123. Kynurenine Aminotransferase I Activity in Human Placenta
  124. On the interactions between antimuscarinic atropine and NMDA receptor antagonists in anticholinesterase-treated mice
  125. Amino Acid Derivatives with Anticonvulsant Activity.
  126. Evidence for Intraocular Synthesis of Kynurenic Acid, a Putative Endogenous Neuroprotectant
  127. Formation of endogenous glutamatergic receptors antagonist kynurenic acid — differences between cortical and spinal cord slices
  128. Proconvulsive effects of the mitochondrial respiratory chain inhibitor — 3-nitropropionic acid
  129. Protection by conventional and new antiepileptic drugs against lindane-induced seizures and lethal effects in mice
  130. NMDA- But Not Kainate-Mediated Events Reduce Efficacy of Some Antiepileptic Drugs Against Generalized Tonic-Clonic Seizures in Mice
  131. AMPA/kainate-related mechanisms contribute to convulsant and proconvulsant effects of 3-nitropropionic acid
  132. Mitochondrial toxin 3-nitropropionic acid evokes seizures in mice
  133. A potential anti-asthmatic drug, CR 2039, enhances the anticonvulsive activity of some antiepileptic drugs against pentetrazol in mice
  134. Felbamate demonstrates low propensity for interaction with methylxanthines and Ca2+ channel modulators against experimental seizures in mice
  135. EFFECT OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ON THE ANTICONVULSIVE ACTIVITY OF VALPROATE AND DIPHENYLHYDANTOIN AGAINST MAXIMAL ELECTROSHOCK-INDUCED SEIZURES IN MICE
  136. Acute ammonia treatment in vitro and in vivo inhibits the synthesis of a neuroprotectant kynurenic acid in rat cerebral cortical slices
  137. Chlormethiazole anticonvulsive efficacy diminished by N-methyl-d-aspartate but not kainate in mice
  138. Excitatory Amino Acid Antagonists Alleviate Convulsive and Toxic Properties of Lindane in Mice
  139. Impairment of brain kynurenic acid production by glutamate metabotropic receptor agonists
  140. Brain‐Specific Modulation of Kynurenic Acid Synthesis in the Rat
  141. Interaction of Calcium Channel Blockers and Excitatory Amino Acid Antagonists with Conventional Antiepileptic Drugs
  142. Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice
  143. Interactions of excitatory amino acid antagonists with conventional antiepileptic drugs
  144. Influence of aminophylline and strychnine on the protective activity of excitatory amino acid antagonists against maximal electroshock-induced convulsions in mice
  145. Influence of combined treatment with NMDA and non-NMDA receptor antagonists on electroconvulsions in mice
  146. Influence of a Ca2+ channel agonist, BAY k-8644, on the anticonvulsant activity of NMDA and non-NMDA receptor antagonists
  147. The competitive NMDA antagonist, D-CPP-ene, potentiates the anticonvulsant activity of conventional antiepileptics against maximal electroshock-induced seizures in mice
  148. The NMDA antagonist procyclidine, but not ifenprodil, enhances the protective efficacy of common antiepileptics against maximal electroshock-induced seizures in mice
  149. Towards an understanding of the role of glutamate in neurodegenerative disorders: energy metabolism and neuropathology
  150. Competitive NMDA receptor antagonists enhance the antielectroshock activity of various antiepileptics
  151. 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline enhances the protective activity of common antiepileptic drugs against maximal electroshock-induced seizures in mice
  152. Competitive antagonist of NMDA receptors, CGP 37849 and CGP 39551, enhance the anticonvulsant activity of valproate against electroconvulsions in mice
  153. Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures
  154. Quinolinate-like neurotoxicity produced by aminooxyacetic acid in rat striatum
  155. Age-related changes in kynurenic acid production in rat brain
  156. Age dependency of the susceptibility of rats to aminooxyacetic acid seizures
  157. NBQX does not affect learning and memory tasks in mice: a comparison with D-CPPene and ifenprodil
  158. Kynurenic Acid: A Potential Pathogen in Brain Disorders
  159. Long-Term Effects of Pilocarpine in Rats: Structural Damage of the Brain Triggers Kindling and Spontaneous I Recurrent Seizures
  160. Aminooxyacetic acid produces excitotoxic lesions in the rat striatum
  161. Influence of MK-801 on the anticonvulsant activity of antiepileptics
  162. Systemic kainic acid administration in rats: Effects on kynurenic acid production in vitro and in vivo
  163. Seizures induced by aminooxyacetic acid in mice: Pharmacolgical characteristics
  164. Paradoxical anticonvulsant acitivity of the ?hyphen;Aminobutyrate antagonist bicuculline methiodide in the rat striatum
  165. Brain-Specific Control of Kynurenic Acid Production by Depolarizing Agents
  166. Excitatory amino acid antagonists and memory: Effect of drugs acting at N-methyl-d-aspartate receptors in learning and memory tasks
  167. Substantia nigra: A site of action of muscle relaxant drugs
  168. Determination of extracellular kynurenic acid in the striatum of unanesthetized rats: Effect of aminooxyacetic acid
  169. Excitatory amino acid antagonists protect mice against seizures induced by bicuculline
  170. Blockade of excitatory neurotransmission in the globus pallidus induces rigidity and akinesia in the rat: implications for excitatory neurotransmission in pathogenesis of Parkinson's diseases
  171. The entopeduncular nucleus regulates muscle tone in genetically spastic rats: role of substance P and γ-aminobutyric acid
  172. Dopamine control of seizure propagation: Intranigral dopamine D1 agonist SKF-38393 enhances susceptibility of seizures
  173. Rat Brain Slices Produce and Liberate Kynurenic Acid upon Exposure to l-Kynurenine
  174. The basal ganglia, the deep prepyriform cortex, and seizure spread: bicuculline is anticonvulsant in the rat striatum.
  175. Homocysteic acid: convulsant action of stereoisomers in mice
  176. Review: Cholinergic mechanisms and epileptogenesis. The seizures induced by pilocarpine: A novel experimental model of intractable epilepsy
  177. Dopamine-sensitive anticonvulsant site in the rat striatum
  178. Differential effects of non-steroidal anti-inflammatory drugs on seizures produced by pilocarpine in rats
  179. Identification and quantification of kynurenic acid in human brain tissue
  180. On the disposition of intrahippocampally injected kynurenic acid in the rat
  181. The susceptibility of rats to pilocarpine-induced seizures is age-dependent
  182. Substantia nigra and motor control in the rat: effect of intranigral α-kainate and γ-d-glutamylaminomethylsulphonate on motility
  183. Effect of Aminophylline and Enprofylline on the Protective Efficacy of Common Antiepileptic Drugs Against Electroconvulsions in Mice
  184. Only certain antiepileptic drugs prevent seizures induced by pilocarpine
  185. Effects ofl-cysteine-sulphinate andl-aspartate, mixed excitatory amino acid agonists, on the membrane potential of cat caudate neurons
  186. Evidence that antagonism at non-NMDA receptors results in anticonvulsant action
  187. Paradoxical anticonvulsant activity of the excitatory amino acid N-methyl-D-aspartate in the rat caudate-putamen.
  188. Convulsant action of morphine, [d-ala2, d-leu5]-enkephalin and naloxone in the rat amygdala: Electroencephalographic, morphological and behavioural sequelae
  189. Seizures produced by pilocarpine: Neuropathological sequelae and activity of glutamate decarboxylase in the rat forebrain
  190. In vitro release and electrophysiological effects in situ of homocysteic acid, an endogenous N-methyl-(D)-aspartic acid agonist, in the mammalian striatum
  191. Effect of Aminophylline on the Protective Action of Common Antiepileptic Drugs Against Electroconvulsions in Mice
  192. Excitatory neurotransmission within substantia nigra pars reticulata regulates threshold for seizures produced by pilocarpine in rats: Effects of intranigral 2-amino-7-phosphonoheptanoate and n-methyl-d-aspartate
  193. Susceptibility to seizures produced by pilocarpine in rats after microinjection of isonnazid or γ-vinyl-GABA into the substantia nigra
  194. Homocysteic Acid, an Endogenous Agonist of NMDA-Receptor: Release, Neuroactivity and Localization
  195. Aminophylline and CGS 8216 Reverse the Protective Action of Diazepam Against Electroconvulsions in Mice
  196. Effects of aminophylline and 2-chloroadenosine on seizures produced by pilocarpine in rats: Morphological and electroencephalographic correlates
  197. Modification of the anticonvulsant activity of 2-amino-5-phosphonovalerate by agents affecting different neurotransmitter systems
  198. Phosphonic analogues of excitatory amino acids raise the threshold for maximal electroconvulsions in mice
  199. Muscle relaxant action of 2-chloroadenosine in genetically spastic rats is independent of γ-aminobutyric acid-mediated inhibition
  200. Effects of morphine and naloxone on pilocarpine-induced convulsions in rats
  201. Muscle relaxant action of excitatory amino acid antagonists
  202. Injections of picrotoxin and bicuculline into the amygdaloid complex of the rat: An electroencephalographic, behavioural and morphological analysis
  203. Seizures produced by pilocarpine in mice: A behavioral, electroencephalographic and morphological analysis
  204. Effect of aminophylline on muscle relaxant action of diazepam and phenobarbitone in genetically spastic rats: Further evidence for a purinergic mechanism in the action of diazepam
  205. Effects of excitatory amino-acid antagonists on the anticonvulsant action of phenobarbital or diphenylhydanton in mice
  206. A specific benzodiazepine antagonist CGS 8216 reverses the muscle relaxant effect of diazepam but not that of phenobarbitone
  207. Differential effects of baclofen, ³-hydroxybutyric acid and muscimol on the protective action of phenobarbital and diphenylhydantoin against maximal electroshock-induced seizures in mice
  208. Studies on the Mechanism of Wet Dog Shakes Produced by Carbachol in Rats
  209. Cholinomimetics produce seizures and brain damage in rats
  210. Limbic seizures produced by pilocarpine in rats: Behavioural, electroencephalographic and neuropathological study
  211. Intrahippocampal bethanechol in rats: Behavioural, electroencephalographic and neuropathological correlates
  212. Does morphine withdrawal produce brain damage in rats?
  213. Intraamygdaloid morphine produces seizures and brain damage in rats
  214. Dyphenylhydantoin enhancement of diazepam effects on locomotor activity in mice
  215. Induction of Wet Dog Shakes by Intracerebroventricular Bethanechol in Rats
  216. Effect of antidepressant drugs on carbachol chloride-induced wet dog shake behaviour in rats
  217. (RS)-α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid: Wet dog shakes, catalepsy and body temperature changes in rats
  218. Effect of combined treatment of phenytoin with diazepam on the susceptibility of mice to electroconvulsions
  219. Effect of trazodone, mianserin, iprindole and zimelidine on wet dog shakes produced by carbachol in rats
  220. Effects of Some Antiepileptic Drugs in Pentetrazol-Induced Convulsions in Mice Lesioned with Kainic Acid
  221. Evidence against the involvement of serotonergic mechanisms in wet dog shake behavior induced by carbachol chloride in rats
  222. Effects of morphine and nalorphine on kainic acid-induced hypothermia in rats
  223. Studies of carbachol-induced wet-dog shake behavior in rats